President Donald Trump signed an executive order on Saturday, April 18, 2026 [1], to accelerate the review and access of psychedelic drug treatments.
This move marks a significant shift in federal policy regarding substances historically viewed as illicit. By expediting the review process, the administration aims to provide faster relief for patients with treatment-resistant conditions, particularly combat veterans struggling with post-traumatic stress disorder (PTSD) [1, 4].
The order, signed in Washington, D.C. [1], focuses on speeding up the medical research pipeline and increasing patient access to specific psychedelic substances. Among the treatments highlighted in the order is ibogaine [1, 2, 3]. The administration intends to reduce the bureaucratic hurdles that have previously slowed the clinical application of these substances in a medical setting [3].
Federal agencies are now directed to prioritize the review of research and treatment options that utilize psychedelic drugs to address mental health crises [1, 4]. The focus on veterans is a primary driver of the order, as the government seeks more effective tools to treat the psychological trauma associated with military service [1, 4].
The order does not immediately legalize these substances for general use but instead streamlines the process for medical research and clinical access [1, 2]. This approach allows the government to maintain regulatory oversight while accelerating the availability of potentially life-saving treatments [3].
“The executive order aims to expedite medical research and treatment options for veterans.”
This executive order signals a pivot toward a more permissive federal approach to psychedelic medicine. By focusing on PTSD and veterans, the administration is leveraging a high-need public health priority to bypass traditional regulatory timelines, potentially creating a blueprint for the medical integration of other controlled substances.
